COLO.B.DK

642.8

-0.22%↓

GMAB.DK

1,322.5

+0.04%↑

AMBUB.DK

103.5

-1.62%↓

COLO.B.DK

642.8

-0.22%↓

GMAB.DK

1,322.5

+0.04%↑

AMBUB.DK

103.5

-1.62%↓

COLO.B.DK

642.8

-0.22%↓

GMAB.DK

1,322.5

+0.04%↑

AMBUB.DK

103.5

-1.62%↓

COLO.B.DK

642.8

-0.22%↓

GMAB.DK

1,322.5

+0.04%↑

AMBUB.DK

103.5

-1.62%↓

COLO.B.DK

642.8

-0.22%↓

GMAB.DK

1,322.5

+0.04%↑

AMBUB.DK

103.5

-1.62%↓

Search

Novo Nordisk A-S (Class B)

Open

437.7 2.81

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

424.75

Max

439.75

Belangrijke statistieken

By Trading Economics

Inkomsten

804M

29B

Verkoop

-7.6B

78B

K/W

Sectorgemiddelde

18.799

56.602

EPS

6.53

Dividendrendement

3.58

Winstmarge

37.182

Werknemers

76,302

EBITDA

4.1B

39B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.53% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.58%

2.45%

Volgende Winsten

6 aug 2025

Volgende Ex Dividend datum

14 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-62B

2T

Vorige openingsprijs

434.89

Vorige sluitingsprijs

437.7

Novo Nordisk A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 mei 2025, 11:36 UTC

Top Nieuws

Novo Nordisk CEO to Step Down Amid Market Challenges

12 mei 2025, 09:36 UTC

Belangrijke Marktbewegers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 mei 2025, 11:29 UTC

Top Nieuws
Winsten
Belangrijke Marktbewegers

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 mei 2025, 07:05 UTC

Winsten

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 mei 2025, 06:19 UTC

Winsten

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

16 mei 2025, 18:35 UTC

Top Nieuws

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mei 2025, 17:34 UTC

Top Nieuws

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 mei 2025, 13:42 UTC

Populaire aandelen

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mei 2025, 13:27 UTC

Marktinformatie

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 mei 2025, 13:15 UTC

Top Nieuws

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 mei 2025, 12:17 UTC

Winsten

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mei 2025, 18:45 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mei 2025, 12:07 UTC

Marktinformatie

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mei 2025, 07:20 UTC

Marktinformatie

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 mei 2025, 15:13 UTC

Winsten

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 mei 2025, 13:56 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mei 2025, 13:45 UTC

Winsten

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 mei 2025, 11:25 UTC

Winsten

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 mei 2025, 11:18 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mei 2025, 09:55 UTC

Winsten

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 mei 2025, 09:36 UTC

Winsten

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 mei 2025, 09:04 UTC

Winsten
Populaire aandelen

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 mei 2025, 08:10 UTC

Marktinformatie

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 mei 2025, 08:08 UTC

Marktinformatie

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 mei 2025, 07:11 UTC

Marktinformatie
Winsten

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

7 mei 2025, 05:39 UTC

Winsten

Novo Nordisk: Sales Outlook Assumes Reduction in Patients on Compounded GLP-1 Treatments During 2H25

7 mei 2025, 05:38 UTC

Winsten

Novo Nordisk 1Q Wegovy Drug Sales Rose 83% To DKK17.36B, Consensus Saw DKK18.5B

7 mei 2025, 05:37 UTC

Winsten

Novo Nordisk 1Q Ozempic Drug Sales Rose 15% To DKK32.72B, Consensus Saw DKK32.01B

7 mei 2025, 05:36 UTC

Winsten

Novo Nordisk 1Q Gross Margin 83.5% Vs 84.8%

Peer Vergelijking

Prijswijziging

Novo Nordisk A-S (Class B) Prognose

Koersdoel

By TipRanks

9.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,162.73 DKK  9.53%

Hoogste 1,550 DKK

Laagste 720 DKK

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novo Nordisk A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

2

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.